AstraZeneca says FDA approves LUMOXITI for certain patients

AstraZeneca and MedImmune, its global biologics research and development arm, announced that the U.S. Food and Drug Administration has approved LUMOXITI for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. LUMOXITI is not recommended in patients with severe renal impairment. The Phase III trial results demonstrated 75% of patients receiving LUMOXITI achieved an overall response; 30% had a durable complete response.